z-logo
Premium
A case of hepatosplenic γ – δ T‐cell lymphoma with a transient response to Fludarabine and Alemtuzumab
Author(s) -
Mittal S.,
Milner B. J.,
Johnston P. W.,
Culligan D. J.
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2006.00646.x
Subject(s) - alemtuzumab , fludarabine , medicine , lymphoma , chemotherapy , regimen , oncology , surgery , cyclophosphamide , transplantation
  Hepatosplenic γ – δ T‐cell lymphoma is a rare, usually fatal lymphoma and available literature on management is sparse. Allografting is probably the only curative option. We describe a further case with a dramatic, though transient response to Fludarabine and Alemtuzumab combination, following a failure of conventional chemotherapy. Given the dreadful prognosis with conventional chemotherapy, it is a regimen worth pursuing as a disease reduction strategy prior to allograft where appropriate.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom